http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106232109-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 |
| filingDate | 2015-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106232109-B |
| titleOfInvention | Pharmaceutical composition use for cancer treatment comprising gossypol and insoral as active constituent |
| abstract | The present invention relates to the pharmaceutical compositions use for cancer treatment comprising gossypol and insoral as active constituent.Specifically, the Combined Treatment of gossypol and insoral is verified to have significant higher anticancer activity compared with the single treatment of gossypol and insoral is used alone.Therefore, the active pharmaceutical composition of the present invention of Synergistic anti-cancer can will is advantageously used in treatment of cancer comprising gossypol and insoral. |
| priorityDate | 2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.